Testing and reporting practices for improved management of hepatitis C

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1403-1407

  Pesano, Rick L ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; INCIVEX; INTERFERON; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; DISEASE SURVEILLANCE; ERADICATION THERAPY; HEALTH CARE MANAGEMENT; HEALTH CARE PRACTICE; HEALTH PROGRAM; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LIVER CANCER; LIVER DISEASE; NUCLEIC ACID TEST; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SEROLOGY; UNITED STATES; VIRAL HEPATITIS SURVEILLANCE PROGRAM; VIREMIA; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS LOAD; VIRUS TRANSMISSION;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; SENTINEL SURVEILLANCE; UNITED STATES;

EID: 84872000775     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2467     Document Type: Review

References (15)

1. World Health Organization. Hepatitis C. (Updated 2002. Accessed 25 January 2012.) Available from http://www.who.int/csr/disease/hepatitis/Hepc.pdf
2. US Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals. (Updated 4 August 2011. Accessed 25 January 2012.) Available from www.cdc.gov/hepatitis/HCV/HCVfaq.htm
3. Bell BP, Manos MM, Zaman A, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol 2008; 103:2727-2736.
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Scott DH. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-278.
5. Institute of Medicine of the National Academies. A national strategy for prevention and control of hepatitis B and C. (Accessed 25 January 2012.) Available from www.iom.edu/viralhepatitis
6. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus MMWR Recomm Rep 2003; 52: 1-13.
7. Mosley JW, Operskalski EA, Tobler LH, et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005; 42:86-92.
8. Ghany MG, Strader DB, Thomas DL, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
9. US Centers for Disease Control and Prevention. Guidelines for viral hepatitis surveillance and case management. (Updated 2 June 2009. Accessed 25 January 2012.) Available from http://www.cdc.gov/hepatitis/statistics/ surveillanceguidelines.htm
10. Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008; 48:398-406.
11. Pockros P, Nelson D, Godofsky E et al. Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40KD), with or without ribavirin: interim analysis results of Phase 2a study. Hepatology 2007; 46 Suppl 1:311A.
12. Le Pogam S, Seshaadri A, Kang H et al. Low level of resistance, low viral fitness and absence of resistance mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo. J Hepatol 2008; 48 Suppl 2:S10.
13. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48:385-397.
14. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604-1612.
15. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.